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Abstract
Prostate cancer, or prostatic carcinoma (PrCa), is the second leading cause of
cancer-related deaths in men in the Western world. One in seven men are
expected to be diagnosed with the disease in the United States. Suppressing
androgen/androgen receptor pathway is a first-line therapeutic treatment known
as Androgen Deprivation Therapy (ADT). Most patients respond well to ADT, but
an overwhelming majority of PrCa progress to an advanced stage of PrCa
independent of hormone, known as Castration Resistant Prostate Cancer
(CRPC). There is currently no known cure for CRPC. In this study, the androgensensitive LNCaP cells served as an in vitro model of ADT. LNCaP cells were
grown without hormone for twenty days and were collected every two days; the
levels of AR protein and its target gene PSA mRNA were examined over this
interval. Full-length AR protein levels appear to remain unchanged throughout
the twenty days, but hormone withdrawal leads to lower PSA levels. In addition,
we also observed the effects of hormonal withdrawal on cell morphology; LNCaP
cells adapted a shape resembling neuronal cells with long and slender
connections between them. Furthermore, the appearance of truncated AR
isoforms occurred during the extended hormonal withdrawal. These findings
suggest that hormonal withdrawal not only suppresses AR activity without
affecting AR protein levels in prostate cancer calls, but also results in the
morphological change.
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Aims:

•

To investigate androgen deprivation on LNCaP cells for twenty days

•

To observe any morphological changes

•

To decrease time interval between collections from preliminary laboratory
work of five days to two days in attempt to intercept possible prostate
cancer cell conversion into CRPC

•

To evaluate changes in AR levels and activity, utilizing PSA mRNA as an
indicator of AR activity

•

To provide any information on long-term withdrawal effects in LNCaP cells
which have been deprived of hormone for thirty, sixty, seventy, and
seventy-four days
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Introduction:
Among the various forms of cancer, prostate cancer (PrCa) is the most
ubiquitous form diagnosed in men and the second-leading cause of cancerrelated deaths. In the United States, one in seven men will be diagnosed with the
disease (1). PrCa is currently a disease with no cure, but androgen deprivation
therapy (ADT) is one of the first-line treatments (2). However, an overwhelming
majority of PrCa progress to an advanced stage, termed castration resistant
prostate cancer (CRPC). Prognosis is poor for men whose PrCa has progressed
into CRPC (3) due to the ability of these prostate cancer cells to proliferate and
survive despite being deprived of androgens that are normally fundamental to the
cells in the prostate. At the crux of prostate cell proliferation is the Androgen
Receptor (AR).
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Figure 1 Androgen Receptor. As shown in figure 1, the AR gene is located in the X chromosome with
8 exons. The transcription factor formed by an amino-terminal transactivation domain (NTD) (exon
1), a carboxyl-terminal ligand-binding domain (LBD) (exons 4-8), a DNA-binding domain (DBD)
(exons 2-3), and a hinge region between the DNA-binding DBD and the steroid binding LBD that
participates in nuclear localization and degradation (24).

The androgen receptor (AR) is a nuclear transcription factor and plays an
essential role in the development and maintenance of the prostate. AR gene is
located on the X chromosome with 8 exons. This transcription factor is formed by
an amino-terminal transactivation domain (NTD) (exon 1), a carboxyl-terminal
ligand-binding domain (LBD) (exons 4-8), a DNA-binding domain (DBD) (exons
2-3), and a hinge region between the DNA-binding DBD and the steroid binding
LBD that participates in nuclear localization and degradation (4). Androgen binds
to the C-terminal LBD.

5

Figure 2 AR signaling. AR is associated with heat shock proteins (HSP) in the cytoplasm when
unbound. Upon binding of androgen, the AR undergoes a conformational change and translocates
to the nucleus as a homodimer, wherein AR binds to AREs (Androgen Responsive Elements) and
transcription follows.

Normally, AR is located in the cytoplasm, associated with Heat Shock Proteins
(HSP). Upon binding of androgens, such as 5α-dihydrotestosterone (DHT) or
testosterone, the AR undergoes a conformational change and translocates to the
nucleus as a homodimer. In the nucleus, AR binds to promoter/enhancer
sequences on AREs (Androgen Responsive Elements) and regulates gene
expression transcriptionally. AR affects a multitude of downstream target genes.
One of the many well-documented downstream target genes of AR is prostate
specific antigen (PSA), which can be used as a serum biomarker for PrCa (5-7).
PSA is a proteolytic enzyme belonging to the kallikrein family of serine proteases
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and produced from the prostatic epithelium. Due to androgen receptor’s crucial
role in the maintenance and development of the prostate, PSA levels have been
used to reflect and monitor AR activity. PSA normally remaining within the
prostate but passes through the gaps into the bloodstream in patients with
prostate cancer (5). Thus, targeting AR pathway via androgen withdrawal is a
first line treatment. Though hormone suppression increases PrCa patient survival
for several years (8), the tumor will progress and eventually relapse to a
metastatic, castration resistant phase.

Figure 3 Primary and redundant AR pathways. Primary pathway with androgen binding (DHT) and
redundant pathways via IL-6R and IGF-1, EGF are depicted. Adapted from Lonergan PE and Tindall
DJ (30).

AR nuclear translocation upon binding of androgens is the primary pathway, but
androgen withdrawal can result in AR translocation independent of androgen via
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alternative, redundant pathways (Figure 3; 9-11). Selective pressures encourage
activity in interleukin-6 (IL-6) and insulin-like growth factor (INF-1) or epidermal
growth factor (EGF) pathways. IL-6 is a pro-inflammatory cytokine circulating in
elevated levels in patients with obesity as well as prior to Type II diabetes
mellitus (Type II) onset. In addition, conflicting studies are available on Type II
providing a protective effect on prostate cancer development, but pooled overall
risk from a meta-analysis of forty-five studies (twenty-nine cohort studies and
sixteen case-control studies) from 1971-2011 by Bansal D et al. showed
decreased risk of prostate cancer in patients with Type II (12).

There appears to be a cross-talk between redundant AR pathways. In the
absence of androgen, IL-6 drives prostate cancer cell proliferation (13) with
evidence suggesting continued AR signaling. Furthermore, IL-6 administration
has been shown to activate tyrosine kinase receptor EGFR and induce
expression of PSA. The proto-oncogene ERBB2 (also known as CD340 or
HER2/neu) was shown to be overexpressed in PrCa progression towards
metastatic androgen independence (10). While IGF-1 has been shown to
stimulate the natural proliferation of prostatic epithelial for normal maintenance
and growth, an overexpression of IGF-1 appears linked to PrCa initiation while
decreased levels are associated with CRPC (14). Similarly, EGF has a role like
IGF-1 as a regulator of normal growth in prostate cell.
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However, while overexpressed IGF-1 appears to encourage initiation of diseased
prostate but not CRPC, overexpression of EGF seems to protect diseased
prostatic cells from apoptosis by inducing BAD phosphorylation via two
redundant

signaling

pathways:

Ras/MEK

and

Rac/PAK1,

resulting

in

phosphorylation on Ser 112 and 136, respectively (11). BAD (BCL-2 associated
death promoter) is a pro-apoptotic protein of programmed cell death pathway
regulators. Thus, BAD can be inactivated by phosphorylation, making either
Ras/MEK or Rac/PAK1 pathways sufficient to protect cells from apoptosis, but
this also means both pathways must be effectively inhibited in order to block
abnormal prostatic cell growth. Essentially, circulating levels of IL-6 or IGF-1/EGF
are found elevated in PrCa. Decreased levels of IGF-1, upregulated levels of
EGFR (15), or increased levels of ERBB2 indicate androgen independent PrCa
advancement towards CRPC utilizing the redundant AR pathways. Gioeli et al.
and Price et al. also found constitutively active ERK/MAPK in advanced CRPC,
providing hints that alternate pathways become implicated in the progression of
PrCa towards CRPC (16, 17).

There is a need for further advancement in the context of CRPC therapies.
Persistent AR nuclear translocation in the absence of hormone can drive prostate
cancer cell proliferation and eventually become castration resistant. Current
treatment of CRPC are two drugs: enzalutamide (an AR antagonist) and
abiraterone (a CYP17A1 inhibitor). While Phase III clinical trials initially showed

9

a survival advantage in patients with CRPC under these two treatments, patients
generally relapsed within a year of treatment, and AR appears to remain active in
the relapsed tumors. In studies performed using LNCaP cells and xenografts, an
increase in enzymes (such as CYP17A1) necessary for de novo steroid
synthesis were found in CRPC sublines. While the increase in these enzymes
could generate measureable levels of hormone, such changes have not been
observed in clinical samples (18). However, recently updated results from the
European Commission’s CORDIS (Community Research and Development
Information Service) at the end of July 2016 addresses a shift towards
investigating resistance to enzalutamide and abiraterone. Hoftland et al. utilized
mice engrafted with human prostate cancer xenografts and ex vivo patient
samples. The results of this ASPIRE-PC study (A novel Androgen Synthesis
Pathway in treatment-REsistant Prostate Cancer) were presented at the
European Congress of Endocrinology and found flux into an alternative adrenal
androgen pathway active within prostate cancer cells that appear to depend on
CYP17A1 activity (19, 20).

Identifying CRPC incidence by ethnicity and location has become somewhat
problematic due to an inability to explain disparities despite adjusting for varying
socioeconomic, demographic, and co-morbid factors. African-American (AA) men
have the world’s highest incidence of PrCa and more than twice the risk of nonHispanic men in presenting with CRPC. In 2001, Hoffman et al. (21) found
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clinically advanced stages of the disease detected more frequently in AA men
than both Hispanic and non-Hispanic white men. However, after adjusting for
socioeconomic, clinical, and pathological factors, increased relative risk of
advanced PrCa was found in Hispanic but not AA men. African-American men
still had a statistically significant increased rate of advanced disease even with
higher socioeconomic status. African-American men appear to present with more
aggressive PrCa due to the highest overall proportion of poorly differentiated
PrCa in all clinical stages except for T2 (tumors confined to the prostate with
suspicious digital-rectal examinations but no evidence of metastases or positive
scans).

A more recent study in 2015 by Spratt DE and Osborne JR assessed recently
published SEER data (National Cancer Institute’s Surveillance, Epidemiology,
and End Results Program) to analyze CRPC risk in all reported ethnicities and
locations in the United States. African-American men to retain an independently
increased risk for CRPC regardless of access to health care (23), which remains
consistent with the results discussed by Hoffman et al. from 2001 (21). This
finding also takes into account recent advances in PrCa treatment that were not
previously available during Hoffman et al.’s 2001 study, including data from
several landmark phase III randomized controlled trials—some of which were
performed by European centers. Additionally, the authors acknowledge the
importance of supporting centers serving large African-American populations,
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such as the North Carolina-Louisiana Prostate Cancer Project and the US FDA
Office of Minority Health (created in 2010) in order to prioritize directed efforts
towards PrCa therapies in AA men.

Another study also released in 2015 by Bell KJL et al. performed a meta-analysis
of all autopsy studies with systematic histological examinations of men who had
no history of pre-existing prostate cancer—twenty-nine studies in more than
twenty countries over a period of sixty years (24). Bell and colleagues reported
similar findings to previously cited reports which also examined age-specific
prevalence with respect to race, finding lowest prevalence in men of Asian
descent, intermediate prevalence in men of European descent, and highest
prevalence in men of African descent. Ultimately, the increased incidence of
CRPC in African-American men remains unknown.

One possibility of higher incidence in advanced stage PrCa in newly-diagnosed
African-American men is that PrCa is a disease of aging, and because men are
generally not encouraged to begin screening until their fifties, African-American
men may have an earlier onset of the disease than other racial groups and may
not catch the cancer until it has already progressed for years. The American
Cancer Society has specifically identified AA men as a high-risk group and
recommends annual screenings beginning at age forty-five for men in this
category (25). Whitney et al. (26) further attempt to differentiate between CRPC
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in both a non-metastatic (localized) and metastatic form with respect to race.
Whitney et al. conclude a lack of association between race and metastases once
age of prostate cancer diagnosis is taken into account. However, although there
appears to be no racial difference of worse outcomes in the later metastases, AA
men are younger at the time of prostate cancer diagnosis, which alludes to the
necessity of being diagnosed earlier than other races in order to undergo
effective treatment to avoid progression towards metastases.

In considering general survival of CRPC cells, there are a variety of mechanisms:
local androgen synthesis (maintenance of residual hormone concentrations
within a tumor), AR amplification (AR overexpression which can increase
sensitivity to low androgen levels), change in ratios between co-activators and
co-repressors (changing the co-regulatory molecules which regulate ligand
sensitivity and AR stability), AR mutations that can broaden ligand specificity,
and alternative splicing to generate different forms AR variants (truncated
isoforms). AR mutations are rare in untreated, early PrCa but common in patients
with CRPC previously treated with a first-generation anti-androgen (27). Of the
possible AR isoforms, splice variant AR-V7 (Figure 4) is the best studied.
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Figure 4 Differences between AR and AR-V7. Diagram depicting the structural differences between
full-length AR and splice variant AR-V7. Diagram by Jacqueline So.

The structural differences between full length AR and splice variant AR-V7 can
be seen in Figure 4. AR-V7 is a shorter, fragmented version of the full-length AR
with intact transactivation and DBDs but not the LBD. Since AR-V7 lacks the Cterminal LBD (AR∆LBD), it serves as a transcription factor in a ligandindependent manner (28, 29).

Since the phase of hormone withdrawal precedes the phase of cancer
progression into metastasis (30), it is imperative to find a connection between
ADT and CRPC development; in particular, withdrawing hormone on an
androgen-sensitive PrCa cell line will provide meaningful clues towards this
progression. In our own lab, preliminary work performed by Peter Wieczorek
found a change in PSA mRNA levels (Figure 5).
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Figure 5 PSA levels in hormone-withdrawn LNCaP cells for 30 days. GAPDH as internal control. RTPCR performed by Peter Wieczorek

The preliminary study found caveats in withdrawing hormone from cells
dependent upon androgen, including discovering that the five-day observation
intervals were too large to see detailed trends in the observed changes from
days five to fifteen without hormone.

Figure 6 Neuroendocrine transdifferentiation. Two different neuroendocrine markers (ChrA and NFM)
show a change in shape of LNCaP cells starved of hormone for five days. Controls in upper level of
both A and B. Farach et al.

Farach et al. treated LNCaP cells with serum starvation (0.1% FBS) for five days.
Neuroendocrine (NE) markers Chromogranin A (ChrA) and Neurofilament M
(NFM)

were

used

to

show

changes

in

morphology

(31)

transdifferentiation—morphology resembling neural cells (Figure 6).

with

NE
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Thus, we decided to withdraw hormone from LNCaP cells for twenty days and
collect cells every two days. In our study, we are interested in the effects of
hormone withdrawal on morphological shifts, AR protein levels and activity
(utilizing PSA mRNA as an indicator), as well as potential splice variants. To
learn the effect of long-term withdrawal on LNCaP cells, we monitored the effect
of hormone withdrawal for thirty, sixty, seventy, and seventy-four days.
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Materials and Methods:
Materials. LNCaP cells were purchased from the American Type Culture
Collection. RPMI 1640 media with phenol-red and L-glutamine, and RPMI 1640
media with L-glutamine but without phenol-red were purchased from Corning
Cellgro. Fetal bovine serum and charcoal treated fetal bovine serum were
purchased from Atlanta Biological. One hundred X antibiotic/antimycotic was
purchased from Gibco Life Technologies. Trypsin (0.03%) was purchased from
PromoCell. Ten cm plates were purchased from CellTreat. Cells were counted
using a Countess ii machine. Cell counting chamber slides and Trypan Blue dye
purchased from Invitrogen. RNeasy purification kits were purchased from
Qiagen. Superscript II Reverse Transcriptase, iBlot, 0.1M DTT, 10mM dNTPs,
qPCR, and PCR primers for PSA and GAPDH were purchased from Invitrogen.
qPCR reagents were purchased from TaKaRa. Fast Western kit, BCA assay kit,
and 96 well plates were purchased from Thermo Fisher Scientific. Precision Plus
Streptactin HRP-conjugate and Protein WesternC Standard were purchased from
BioRad. From Invitrogen, antibodies AR-N20, Beta-tubulin, and AR-C19 were
also purchased. Antibody AR-V7 was purchased from Abcam. GoTaq Flexi DNA
polymerase was purchased from ProMega. All purpose Hi-Lo DNA marker
purchased from Bionexus, Inc. All media was kept at 4°C. Enzymes and primers
were kept at -20°C. RNA,cDNA, and protein lysate were stored at -30°C.
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Cell Culture & Treatment. LNCaP cells were cultured in 10cm petri dishes in
10mL of RPMI 1640 media with phenol-red and L-glutamate and supplemented
with 10% fetal bovine serum (FBS) and 1% antibiotic/antimycotic. Cells were
maintained in a fisher scientific incubator at 37°C and 5% CO2. When cells grew
to 80% confluence, they were shifted to either media with regular FBS (RPMI
1640 media with phenol-red and L-glutamate, supplemented with 10% Fetal
Bovine Serum and 1% antibiotic/antimycotic) or media with charcoal-treated
serum

(RPMI

1640

media

with

L-glutamate

and

without

phenol-red,

supplemented with 10% Charcoal-treated Fetal Bovine Serum and 1%
antibiotic/antimycotic). Photos documenting of cell shape changes were taken
under microscope with 4x, 10x, 20x, and 40x magnification using consistent
settings across all days.
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Cell Counting and collecting.

Figure 7 Cell Culturing Timeline. Cells are collected every two days. Project starts with LNCaP cells
growing in media with regular FBS on six 10cm plates. One plate is collected to serve as Day 0
(Control). Five plates remain. One more plate is collected on Day 2; the remaining four plates on Day
2 are split into six plates, with equal distribution of the total cell growth from the previous phase.
Day 4 begins with six plates again, one is collected, five remain, and the process continues in this
manner for the entire project. Diagram by Jacqueline So.

As depicted in Figure 7, collection periods begin with six plates of cells. Cells
were collected every two days and split every other collection. The first plate is
collected, serving as Day 0; five plates of cells remain. After two days, a second
plate is collected, serving as Day 2. For sub-culturing, four plates remain after
this collection and they were trypsinized, re-suspended and combined into a
50mL conical tube and centrifuged at 3000 rpm for five minutes. Excess media
was aspirated and re-suspended into 12mL of growth media. Then, 2mL of cell
suspension was combined with 8mL of growth media and plated to 10cm plates.
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For each collection, cells were trypsinized and re-suspended in 3mL of their
growth media. A portion of the re-suspended cells and Trypan Blue dye were
combined in a 1:1 ratio of 20uL each onto the Countess cell counting chamber
slide and analyzed in the Countess ii machine. The remaining re-suspended cells
were centrifuged at 3000 rpm for 5 minutes. Media was aspirated with 1mL
leftover, and the cells were re-suspended in the remaining 1mL media; 500uL of
this new suspension was aliquoted to two eppendorf tubes. Transferred cells
were centrifuged at 2500 rpm for minutes and excess media was aspirated and
the pellets were stored at -30oC for Western blotting or RT-PCR.

RNA Purification & RT-PCR. RNA was extracted with an RNeasy kit from
Qiagen as per manufacturer’s instruction. Total RNA concentrations were
quantified using a Nanodrop 2000. After verifying the purity and concentration of
the RNA, cDNA was prepared using 5µg of RNA by adding appropriate volumes
of RNA, RGDD, and 10µM random primers (9 bp) to thin-walled PCR tubes;
samples were then denatured at 65°C for 5 min to break hairpins and secondary
RNA structures before cDNA generation. Mastermix including 1st Strand Buffer
5X, Reverse Transcriptase, 0.1M DTT, and 10mM dNTPs were added to each
sample before undergoing cDNA generation in the thermocycler: 25°C for
10min., 42°C for 50min., and 70°C for 15min. cDNA generated from this process
was then diluted five times with RNase-free water and used as a template for
PCR. 5µlof cDNA was added to new, thin-walled PCR tubes in preparation for
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adding the appropriate sub-mastermixes afterwards. Mastermix with 5X Green
Buffer, GoTaq flexi DNA polymerase, RGDD, 25mM MgCl2, and 10mM dNTPs
were

added

to

each

sub-mastermix,

AGCACCAGCCACCAACCT

GC-3’)

which

had

either

or

PSA

(5’-

GAPDH(5’-

ACAGCCTCAAGATCATCAGCAA-3’) primers. The PSA primers were prepared
from [100µM] stock, and the GAPDH primers were prepared from [50µM] stock.
Primers were diluted to a working concentration of 10µM before being added to
the sub-mastermixes, which were then distributed to the respective samples
each with 1µg of cDNA and placed in the thermocycler: 29+ cycles of 95°C for
1min, 60°C for 1 min, 72°C for 1min.

Gel Electrophoresis. PCR samples were separated on a 1% agarose gel (10µg
Ethidium Bromide). All-purpose Hi-Lo DNA ladder was used as a molecular
weight marker, and the gel was run at 70-71V for 40 minutes.

cDNA test. To determine whether cDNA was successfully reverse transcribed, a
cDNA test using gel electrophoresis was performed with cDNA samples of
interest: 10uL of sample was combined with 5uL of 5X Green Buffer in a PCR
tube, and all 15uL were pipetted into their respective wells. After the gel finished
running, results were visualized using the QuantityOne software on a VersaDoc
machine to detect smears, indicating successful reverse transcription.
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Western Blot. Cell lysate was made from the cell pellet using RIPA (1M Tris-Cl,
5M NaCL, 100% NP40, 10% DOC, 10% SDS, 0.1M DTT, 0.1M PMSF, and 100X
PIC) for 20 minutes on ice and centrifuged for 45 minutes at 15,000 rpm. Proteinrich supernatant was transferred to new tubes and the cell debris was discarded.
Protein concentrations in the lysates were measured by BCA assays. Lysate with
50µg protein was prepared with appropriate amounts of 2X SDS and RGDD
before denatured at 95°C for 5 minutes. Proteins in the lysates were separated
by SDS-PAGE. 10µL Fast Western Precision Plus Protein Standard was loaded
into a well. After the run-time finished, the gel was transferred to a nitrocellulose
membrane using an iBlot. The membrane was briefly covered in Ponceau Red in
order to detect protein and determine whether the protein successfully
transferred. The blot was then blocked with Fast Western Antibody Diluent for 1
or more hours before adding the primary antibody (AR N-20, AR-C19, or AR-V7)
in a dilution of 1:5000 and incubated overnight on a rocker at 4°C followed by
three 15-minute washes with PBS-tween (0.1%). Afterwards, 0.55µL Precision
Plus Streptactin HRP-conjugate, 0.5mL HRP conjugate, and 5mL diluent were
added to the membrane for 10 minutes followed by washing three times with
PBS-tween for 15-minutes per wash. Clarity Western ECL Substrate was used to
visualize the blot via chemiluminescence. Quantity One software generated
images through densitometry. The blot was washed and probed with β-tubulin to
confirm equivalent loading. Before re-probing with AR-C19 and AR-V7, the blot
was stripped.
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Results:
Morphological changes on LNCaP hormone-withdrawn cells

Figure 8 LNCaP morphology in hormonal withdrawal. Morphological changes as observed in
hormone-deprived LNCaP cells for twenty days. Control in upper left and bottom right corners (Day
0). Shifts in morphology become apparent on Day 8 without hormone. Representative slender
processes as observed are boxed on Days 8 and 12 for comparison. All magnifications at 40x.

Figure 8 shows the changes in LNCaP shape without hormone when viewed at
40x for the duration of twenty days. On Day 0, LNCaP cells appear to have
adherent and semi-adherent qualities. They grow as aggregates and form
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multiple connections with surrounding cells to create a web-like cluster and cover
any remaining spaces on the plate. After hormone withdrawing for 2 days, cells
appear to have grown slower with some cell death apparent. Day 4 depicts the
re-growth of the cells after being re-plated without hormone; the abundance of
individual spindle shapes with robust connections is visibly less. Day 6 is
observed two days after re-plating, and the shape of the connections begins to
visually deviate from control. Remaining plates are combined and re-plated to
generate the cells viewed on Day 8.

Changes in morphology become apparent on Day 8, where the growth appears
to have dramatically reduced and the previously robust connections have
become long and thin between the fewer cells which have proliferated. Day 10
sees retention in the shift towards these slender processes, and the change in
morphology persists in the remaining days shown (Day 12, Day 14, Day 16, Day
18, Day 20) when compared with control. The overall formation of hormonedeprived LNCaP cells for twenty days follows a transition from being
characteristically adherent with multiple attachments to all surrounding cells into
a shape resembling neural cells with a single cell body and long, thin
connections.
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Figure 9 Reproducible morphological changes. Morphological changes are observed only in the
hormone-withdrawn LNCaP cells (top two rows, “ADT”) and not the control set (“FBS”). All photos at
10x magnification.

Four separate hormone-withdrawn LNCaP cells for twenty days were collected
every two days, and the trend of morphological changes becoming apparent on
the eighth day without hormone was observed in all collections. The cells also
appeared to be less abundant on the eighth day without hormone, correlating to
increased cellular death. However, the cells are observed to re-proliferate again
following the eighth day. This unique observation was of particular interest, so
the hormone-withdrawn experiment was repeated again along with a control set
of LNCaP cells grown in media with regular FBS (not deprived of hormone).

The cells in the new repeated experiment were carefully monitored for a time
period of fourteen days in order to observe whether the previously-viewed trend
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of decreased abundance on Day 8 and the following re-proliferation with
morphological changes was reproducible. We again observed the trend of
dramatic cell death in the hormone-deprived cells on the eighth day (Figure 9). Of
note, Day 8 is the first day following a re-plating of cells, but the growth of the
hormone-withdrawn sets (“ADT”) is visibly slower than the growth of the control
set (LNCaP cells grown and cultured in hormone, “FBS”). Day 12 also represents
the cells after a re-plating from Day 10, but only in the hormone-withdrawn sets
are morphological changes established. Withdrawing hormone on LNCaP cells
resulted in immediate slower growth (depicted in Figure 9) and a change in
morphology not found in LNCaP cells grown in media with regular FBS serum.
The overall trend of changes in LNCaP shape is reproducible with hormonal
withdrawal; the shape shifts from abundantly small cells with robust spindle
formations connecting adjoining cells in a web-like manner to becoming
physically similar to neural cells: larger cell body with elongated, slender
projections.
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Effect of hormone deprivation on PSA levels in LNCaP cells

Figure 10, A-B LNCaP PSA expression under hormonal withdrawal. A) PSA levels as representative
of AR activity in hormone-withdrawn LNCaP cells for twenty days. GAPDH as internal control. 10uL
of each sample was loaded into the wells. PSA levels for Day 18 and Day 20 were run on a separate
gel with Day 0. 10uL of each sample was loaded into the wells. GAPDH as internal control. B) RTPCR of all hormone-withdrawn LNCaP samples from a separate collection run on the same gel with
smaller wells, provided for reference of the observed trend. 8uL of each sample was loaded into the
wells. PSA levels decrease throughout the twenty days. GAPDH as an internal control. Considering
GAPDH levels, there appears to be no difference between Day 0 and Day 2 in PSA expression, but
the levels decrease for the remaining days of LNCaP androgen deprivation when compared to
control.

Figure 10 (A-B) represents the reproducible trend observed in all twenty-day
hormone-withdrawn collections. Our results suggest that hormone withdrawal
leads to lower levels of PSA levels. Since one gel could only accommodate a
DNA ladder and samples for Days 0 through 16, samples for Days 18 and 20
were run with a control on a separate gel; results from both gels are combined
into one image (A). Another set of PCR products was run using smaller wells to
include all samples (B). PSA expression does not appear to change much for the
first two days without hormone, similar to what is viewed in the PSA mRNA levels
seen in Figure 10-A. PSA is lower throughout the remaining days when
compared to control.
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Effects of hormonal withdrawal on AR protein levels:

Figure 11 LNCaP AR protein levels under hormonal withdrawal. Results are shown of androgen
deprivation on AR protein levels in LNCaP cells for twenty days as analyzed via Western Blot with
antibody for full-length AR (AR-N20). Beta-tubulin is used as a loading control. AR protein levels do
not appear to change throughout the twenty days without hormone.

PSA is one of the well-established target genes of AR (18). Reduced PSA levels
suggests a lower AR activity. We then decide to explore the possibility that
reduced PSA levels are the results of reduced AR protein expression in the
LNCaP cells. In order to determine AR levels, antibody AR-N20 was used to
probe for full-length AR, which falls at 110 kDa. The intensities of these bands
were determined using chemiluminescence before visualizing with QuantityOne
software. Beta-tubulin was used as a loading control for all Western Blots. Figure
11 is representative of the trend observed in Western Blots for all twenty-day
collections. AR protein levels appear to remain fairly consistent. It appears to be
an increase in AR levels at Day 6; however, the level of Beta-tubulin suggests
uneven proteins loaded for that sample relative to Day 4.
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Possible Splice Variants

PSA mRNA levels appear to change throughout the twenty days (Figure 10, AB), suggesting a change in AR activity even though the AR protein levels appear
unchanged throughout the same time period (Figure 11). Thus, the Western Blot
was stripped and re-probed with antibodies AR-C19 and AR-V7 to look for
possible splice variants. Figure 12 shows that truncated isoforms of the AR were
found at ~75kDa on Day 8 and Days 14 through 20 with both antibodies AR-C19
(A) and AR-V7 (B).

Figure 12, A-D Induced splice variants. When the blot was probed with antibody AR-C19, splice
variants appeared at 75 kDa on Day 8, and Days 14 through Day 20. Full length AR can be seen at
110 kDa (A). Splice variants with the molecular weight of 75 kDa also appeared after stripping and
probing the blot using antibody AR-V7 (B). Entire Western Blot probed with AR-N20 provided as a
reference (C). Ponceau S Stain depicting total levels of protein, provided as a reference (D).

The finding of splice variants correlates to the morphology shifts observed in the
hormone-withdrawn LNCaP cells during the same time points. AR-V7 does not
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retain the C-terminal LBD, which allows this splice variant to serve as a
transcription factor in a ligand-independent manner (independent of hormone). A
surprising find was the induction of a splice variant which has retained the Cterminal domain, as recognized by Antibody AR-C19. The ~75 kDa range of the
blot remains fairly unremarkable until Day 8, where a distinct band is viewed; this
distinct band disappears to return on Day 14 and remains at a consistent level for
the remaining duration. To ensure the observation of these distinct bands at the
lower molecular weight, both the immunoblot using AR-N20 and Ponceau S Stain
were examined for bands in the range of 75-80 kDa which may have stained
greater than others. No bands are more apparent than the preceding or following
bands in either the western blot with AR-N20 (C) or the Ponceau S Stain showing
total levels of protein (D), suggesting the appearance of splice variants is not an
artifact.
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Effects of Long-term Withdrawal: Morphology

Figure 13 LNCaP Morphology in long-term hormonal withdrawal. LNCaP cells were maintained in
hormone-starved serum for up to 74 days. Days 0 and 20 are provided as references. Morphological
changes are maintained in the long-term withdrawal. All photos are at 40x magnification.

In addition to the twenty-day collections, LNCaP cells were also maintained in
hormone-free media for up to seventy-four days to observe long-term effects of
any further morphological changes (Figure 13). Cells were monitored and
collected at Days 30, 60, 70, and 74. In Figure 12, Days 0 and 20 are provided
as references of LNCaP morphological changes. Changes in shape of LNCaP
cells with prolonged androgen deprivation did not revert back to control. As
observed on Days 30, 60, 70, and 74, the continued proliferation of these
hormone-deprived cells continued to consist of singular, round cell bodies with
long projections. The cell bodies have become rounder with less projections
stemming from each cell, but those projections have become visibly longer. The
long-term hormone-withdrawn cells appear to cluster in a lattice framework with
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needlepoint projections. Furthermore, the individual cell bodies of LNCaP are
noticeably larger and more apparent than control.

Long-term Withdrawal Effects on AR:

Figure 14 AR protein level on Day 74. Western Blot in long-term androgen deprivation, probing with
antibody AR-N20 for full-length AR, which falls at 110kDa. Day 0 as negative control; Beta-tubulin is
used as a loading control. AR protein levels appear unchanged throughout the long-term
observation (74 days without hormone).

A Western Blot was performed on long-term hormone-withdrawn LNCaP cells to
determine whether AR protein levels changed (Figure 14). A sample from Day 0
serves as control, and a sample from Day 74 represents LNCaP cells growing for
long-term hormone withdrawal. The Beta-tubulin for Day 74 is comparable to that
at Day 0 and AR protein level appears unchanged.

Long-term Withdrawal Effects on PSA Expression:
PSA mRNA levels for days 30, 60, 70, and 74 without hormone are shown
(Figure 15, A). Day 0 serves as the basal level. GAPDH for Days 70 and 74 are
comparable to control, but the PSA expression is dramatically reduced. Faint
bands can still be seen at Days 70 and 74, suggesting that though PSA mRNA
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levels greatly decreased, it is still expressed in long-term hormonal withdrawal.
These results indicate that though AR protein levels remain unchanged in longterm withdrawal (Figure 14), AR activity does change.

Figure 15, A-B PSA expression in long-term hormonal withdrawal. RT-PCR performed using samples
from LNCaP cells deprived of hormone for 30, 60, 70, and 74 days (A). A cDNA test shows that the
cDNA for long-term withdrawal samples were successfully reverse transcribed (B). Day 0 is the
control. PSA mRNA indicates AR activity. GAPDH serves as an internal control.

To account for the absent PSA and decreased GAPDH bands for samples from
Day 30 and Day 60 without hormone, a cDNA test was performed (Figure 15, B).
The result was visualized using QuantityOne software on a VersaDoc machine. If
cDNA was successfully reverse-transcribed, a smear would appear in the
respective lanes showing the extent of fragmentation. Figure 15 (B) shows that
cDNA for samples Day 30, Day 60, Day 70, Day 74, and Day 0 (control) were
successfully reverse-transcribed.
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Discussion:
Our project addresses the caveats from the preliminary work in studying the
effects of hormone deprivation on hormone-sensitive LNCaP prostate cancer
cells, using phenotypic observations for twenty days as our guide to narrowing
the scope of when regular prostate cancer cells begin transitioning into castration
resistant prostate cancer cells. We adjusted our cell culturing timeline and the
number of cells plated. In order to account for slower LNCaP growth when
deprived of hormone, we retained total cell growth from one phase and evenly
distributed that for the next growth phase; this ensures having enough cells to be
collected every two days for the duration of the project. However, we
acknowledged there may be inseparable variables contributing to our results,
such as cell density in addition to hormone deprivation.

The exact impact that cell density has on growth is unknown, but previous work
by Sieh S. et al. studied the phenotypic characteristics of LNCaP cells allowed to
grow up to certain densities in a bioengineered, hypoxic environment; utilizing
their 3D models. Sieh et al. described the appearance of multiple “finger-like”
structures in LNCaP colonies after hypoxic conditions for twenty-eight days (32).
The study mentions additional previous work by Anderson et al. (33) describing
adaptive tumor cells in 3D cell culture acquiring similar morphology under
nutrient-depleted or hypoxic conditions. Thus, while our study fails to account for
confounding variables with respect to effects from cell density, our morphological
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observations are still comparable with those described by previous 3D modeling
work which adjusted for LNCaP cell size or density. This reassures us that our
results are still meaningful and can provide another perspective into LNCaP
hormonal withdrawal when selecting for retaining total cell growth in culture.

To determine whether hormone-sensitive LNCaP cells appear to alter
themselves during androgen withdrawal, we looked at the effects of AR levels
and AR activity in these deprived cells using PSA mRNA levels as an indicator.
In addition, four collections of hormone-withdrawn cells were collected every two
days for twenty days, with observed morphological shifts in the LNCaP cells
documented at 4x, 10x, 20x, and 40x magnifications; cell counts and
concentrations were also performed.

Our findings are consistent with previous studies including preliminary work in
our lab. Throughout the twenty-day project, we observed repeatable, sustained
morphology phenotypically resembling neural cells in hormone-withdrawn LNCaP
cells, consistent with changes in morphology found by other studies (31, 34, 35).
We also observed changing levels of PSA consistent with our preliminary
findings, and we were able to view changes occurring in the hormone-withdrawn
cells more closely due to narrowed observation periods from five-day intervals to
two. However, despite a change in PSA mRNA levels, we observed no stark
differences in AR protein levels throughout the twenty days. We also found AR
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truncated isoforms appearing at ~75 kDa on Day 8 without hormone when the
blot was probed with antibodies against either AR-C19 or AR-V7.

The appearance of splice variants at the lower molecular weight after several
days without hormone indicates the concurrent changes in AR with progression
of PrCa cells. This finding suggests an alternative mechanism in AR
transcriptional regulation of the target gene expression separate from using the
full-length AR. This finding also warrants more investigation into discovering the
connection between a splice variant which has retained the C-LBD and one
which does not recognize the C-LBD; how these variants regulate gene
expression with prolonged hormonal withdrawal in our study has yet to be
determined, but the discovery of these AR truncated isoforms around a similar
phase of hormone deprivation in LNCaP cells suggests that the PrCa has
transitioned into CRPC, as indicated by several other studies (36-38).

The timing behind LNCaP transdifferentiation and the appearance of AR splice
variants appears to be curiously synchronized in some manner, but the exact
mechanisms behind them are still being explored by our lab and other studies. In
our study, the proclivity of hormone-withdrawn LNCaP prostate cancer cells to
transition into a castrate resistant state can be hinted by the appearance of splice
variants. The induction of splice variants with prolonged androgen deprivation is
particularly exciting because these findings are consistent with a fairly recent
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study (2013) performed by Mudryj M. and Tepper CG, who describe truncated
ARs lacking a regulatory LBD as a novel mechanism in evading androgen
deprivation, as well as proteolysis of full-length AR as one mechanism that
results in the expression of AR∆LBD (28). LNCaP cells normally do not exhibit
detectable levels of the splice variant lacking the C-terminal LBD (AR∆LBD), but
the findings of our project agree with those observed by previous studies, which
found that C-terminally truncated AR isoforms could be induced in LNCaP cells
(39), and androgen deprivation also was found to enhance levels of the Cterminally truncated AR isoform in LNCaP cells (40).

It is possible that redundant AR pathways involving IL-6, IGF-1, or EGF might
have been selected over time, but antibodies selecting for activity in these
pathways (such as Ser112 for the Ras/MEK cascade) would be necessary in order
to confirm this suspicion. Furthermore, utilizing NE markers to monitor the
appearance

and

retention

of

the

NE

phenotype

would

validate

the

transdifferentiation we observed, as well as allow us to more accurately
coordinate the timeline of activities and cellular changes under androgen
deprivation duress. Qiu et al. found IL-6 treatment and Kim et al. found activating
EGFR via ERK/MAPK induced LNCaP NE differentiation (41, 42). However,
despite suggestions by previous studies of PrCa cell NE transdifferentiation
through multiple pathways, it is difficult to compare the clinical progression for
underlying mechanisms due to transdifferentiated cells being shown to revert
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back to their original phenotype upon the re-introduction of hormone (15, 34).
Shen et al. induced NE differentiation within five days of LNCaP cells cultured in
chronic hormone-deprived medium, the altered morphology predominating at ten
days, and a complete transformation observed by twenty days. However, Shen
and colleagues noted a reversal in the morphology when the medium was
entirely replaced by that containing unmodified FBS and not a reversal when
DHT was directly added into the hormone-deprived medium (43). Thus, in order
to determine any form of molecular basis for NE differentiation, establishing PrCa
cells which retain their NE characteristics to resemble terminally differentiated
clinical PrCa cells becomes pertinent.

A comprehensive review by Yuan TC et al. (44) attempted to answer this
conundrum after successfully establishing stable “NE-like” subclone of LNCaP
cells after hormone deprivation. Even after three-months of re-culturing in
medium containing androgens, the cells in the subclone did not revert back to
their original phenotype and still express NE markers. Yuan and colleagues
described these subclones as ideal model for characterization due to the
resemblance of terminal transdifferentiation in clinical samples. They found a lack
of AR or PSA expression and suggest factors in this differentiation to be induced
through several alternate pathways, such as IL-6, EGFR, and especially RasERK/MAPK. Relating Yuan and colleagues’ stable NE-like LNCaP cells to our
tangential, prolonged study (hormone-deprived LNCaP cells for seventy-four
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days), we saw a dramatic reduction in PSA expression but not AR. We did not
reintroduce hormone into these cells to determine whether the morphological
changes were stable, though we have reason to believe the resiliency of these
changes as phenotypic observations at thirty days and beyond appeared even
more dramatic. Perhaps a differing level of AR expression between Yuan et al.’s
findings and ours can be related back to the effects of cell density, but we would
have to repeat our extended period with varying densities to confirm this.

In summary, despite an unknown variable of cell density effects on our results,
our repeatable morphological observations remain consistent with works
performed by other studies showing LNCaP transdifferentiation to cells
resembling the neural cell morphology. Furthermore, we observed long-term
effects of androgen withdrawal on LNCaP cells. Passages of LNCaP cells which
have been deprived of hormone for the following days are: six times for thirty
days; eight times for sixty days; nine times for seventy days; and ten times for
seventy-four days. We found that LNCaP cells were able to survive without
hormone for seventy-four days while retaining the morphological changes. We
also found a dramatic decrease in PSA mRNA levels for Days 70 and 74
compared to control, though PSA could still be expressed. However, there was
no apparent change in AR protein levels comparing Day 0 to Day 74, suggesting
a change in the activity as a possible mechanism for prolonged survival in the
androgen-independent state.
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In addition to utilizing neuroendocrine markers, such as ChrA, NFM, NSE
(neuron specific enolase), NeuN (neuronal nuclear protein), or S-100 (astrocyte
marker) to validate the morphological shifts we repeatedly observed, our future
work will require furthering our tangential project: the long-term effects of
androgen deprivation on LNCaP cells for seventy-four days. By studying the
LNCaP cells for this extended duration repeatedly, we will be able to confirm that
our observations with the extended findings are reproducible. In repeating this
project at least once more, we will consider verifying the LNCaP cell line from the
ATCC website and synchronizing the cells prior to commencing treatment.

To conclude, ADT is a widely-used therapeutic treatment for PrCa to prolong
survival for several years, especially when combined with other therapies.
However, hormone-refractory PrCa can occur, leading to CRPC through
mechanisms poorly understood. In this study, our data imply that androgen
deprivation not only generated a C-terminally truncated AR isoform, but that a
splice variant with the C-domain retained may be possible as well. Therefore,
withdrawing hormone in hormone-sensitive prostate cancer cells result in
changes in morphology, induction of splice variants, and no overall change in AR
protein levels but a change in AR activity.

Our findings warrant more work to validate and further elucidate the biochemical
mechanisms. We have shown evidence of time-sensitive treatment of prostate
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cancer cells undergoing androgen independence when the cells are allowed to
grow in total form, undeterred from possible mechanical selection biases since
total growth from each previous growth was retained and evenly distributed to
observe the next growth phase. It can be possible to over treat or extend a first
line of defense therapy beyond a beneficial window. In vitro, we have shown that
it is possible to do more harm to a potential patient when androgen withdrawal no
longer becomes effective on reducing prostate cancer cellular growth despite
lower levels of PSA as an AR indicator. Thus, we have found that solely using
PSA as a marker of PrCa level is unreliable once PrCa cells appear to have
established NE-like features, possibly retaining them in the long-term CRPC
state.

Our work hints at using NE markers at the onset of treatment and during in order
to determine whether the NE levels have changed. If the NE levels appear to
markedly increase in the prostatic epithelia or surrounding tissue, this may serve
as a more reliable indicator of CRPC progression and the necessity to change
treatments. So that the available options do not exhaust their effectiveness,
perhaps it will behoove clinicians to consider monitoring NE levels before
beginning ADT, then stopping ADT once NE levels rise. After stopping ADT,
clinicians may consider targeting the alternative AR-pathways.
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Since there are currently no known primary prevention strategies for PrCa, preemptive clinical focus should be placed on early stage prevention strategies,
such as education on the time-sensitive nature of hormonal withdrawal and how
the age of presentation may be different for individuals depending on other
potential comorbidities, such as obesity or diabetes (especially type II). The
American Cancer Society recommends PrCa screening to begin at age forty-five
for high risk groups and at age forty for higher risk groups (25), but perhaps
patients who are obese or have diabetes should begin screening for PrCa in
young adulthood instead of in their forties. Especially since African-American
men have been found to be both younger at the time of initial PrCa diagnosis
(26) and have obesity linked to PrCa (45, 46), clinicians and researchers would
have a better likelihood of finding any racial differences in PrCa progression by
comparing early stages and diagnosis.

The correlation between the appearance of splice variants with morphological
shifts further emphasizes the important of identifying biomarkers that can help
clinicians to choose the best treatment options for patients depending on
androgen-independent phase, lifestyle, and possible comorbidities. Furthermore,
it may be better to use different treatments for patients with diabetes, obesity,
and even abnormal vertical growth (IL-6, JAK/STAT, IGF-1/EGF, Ras/MEK,
Ras/Ack, P13K/Akt, Ras or MEK to Src, etc.). We found that LNCaP cells survive
up to seventy-four days without hormone while maintaining morphological
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changes concurrent with barely expressing PSA levels. This means that low PSA
levels do not necessarily correlate to a cancer being in remission. Previous
therapeutic options following CRPC were limited to second-line therapies with
limited clinical benefit due to eventual relapse within a year or two (3, 8, 47). The
data from this study suggest that new agents targeting the alternative AR
signaling axis could be used in treating CRPC.
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